MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the efficacy and safety of an investigational medication
for improving symptoms of Alzheimer's Disease. Subjects will receive either active medication
or placebo for 28 days. Tests of memory, concentration will be included. Safety will be
monitored using routine clinical and laboratory tests.